These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 27509718

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Evaluation of the latex turbidimetric immunoassay for CK-MB protein].
    Okubo M, Kimura S, Matsui M, Suehisa E, Hidaka Y.
    Rinsho Byori; 2013 Nov; 61(11):989-94. PubMed ID: 24450103
    [Abstract] [Full Text] [Related]

  • 4. [Establishment of a cut-off value for the diagnosis of acute myocardial infarction using a new CK-MB activity measurement reagent containing anti-MtCK antibody].
    Murakami M, Kodama M, Yoshida R, Asada T, Sano T, Sano M, Kamakura S, Nonogi H.
    Rinsho Byori; 2011 Jul; 59(7):649-55. PubMed ID: 21874790
    [Abstract] [Full Text] [Related]

  • 5. Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies.
    Hoshino T, Sakai Y, Yamashita K, Shirahase Y, Sakaguchi K, Asaeda A, Kishi K, Schlattner U, Wallimann T, Yanai M, Kumasaka K.
    Scand J Clin Lab Invest; 2009 Jul; 69(6):687-95. PubMed ID: 19484658
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting.
    Le RD, Kosowsky JM, Landman AB, Bixho I, Melanson SE, Tanasijevic MJ.
    Am J Emerg Med; 2015 Jan; 33(1):72-5. PubMed ID: 25455047
    [Abstract] [Full Text] [Related]

  • 8. Analytical performance of time-resolved fluorometry-based Innotrac Aio! cardiac marker immunoassays.
    Hedberg P, Valkama J, Puukka M.
    Scand J Clin Lab Invest; 2003 Jan; 63(1):55-64. PubMed ID: 12729070
    [Abstract] [Full Text] [Related]

  • 9. Weak diagnostic performance of troponin, creatine kinase and creatine kinase-MB to diagnose or exclude myocardial infarction after successful resuscitation.
    Kruse JM, Enghard P, Schröder T, Hasper D, Kühnle Y, Jörres A, Storm C.
    Int J Cardiol; 2014 May 01; 173(2):216-21. PubMed ID: 24636545
    [Abstract] [Full Text] [Related]

  • 10. Clinically effective CK-MB reporting: how to do it?
    Vivekanandan S, Swaminathan R.
    J Postgrad Med; 2010 May 01; 56(3):226-8. PubMed ID: 20739777
    [Abstract] [Full Text] [Related]

  • 11. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
    Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW, Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ.
    Am Heart J; 2006 Jan 01; 151(1):16-24. PubMed ID: 16368286
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular disease testing on the Dimension Vista system: biomarkers of acute coronary syndromes.
    Kelley WE, Lockwood CM, Cervelli DR, Sterner J, Scott MG, Duh SH, Christenson RH.
    Clin Biochem; 2009 Sep 01; 42(13-14):1444-51. PubMed ID: 19523464
    [Abstract] [Full Text] [Related]

  • 13. Heart-type fatty acid binding protein--a reliable marker of myocardial necrosis in a heterogeneous group of patients with acute coronary syndrome without persistent ST elevation.
    Figiel Ł, Kasprzak JD, Peruga J, Lipiec P, Drozdz J, Krzemińska-Pakuła M, Smigielski J.
    Kardiol Pol; 2008 Mar 01; 66(3):253-9, discussion 260-1. PubMed ID: 18393112
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the chemiluminescence immunoassays for the measurement of troponin I, myoglobin and CK-MB using the IMMULITE system in comparison to other measuring systems.
    Lestin M, Hergert M, Lestin HG, Brinker C, Storm H, Kuhrt E, Kuhrt B, Lambrecht HG, Kühnel W.
    Clin Lab; 2002 Mar 01; 48(3-4):211-21. PubMed ID: 11934224
    [Abstract] [Full Text] [Related]

  • 15. Financial impact of a rapid CK-MB-specific immunoassay on the diagnosis of myocardial infarction.
    Apple FS, Preese LM, Riley L, Gerken KL, Van Lente F.
    Arch Pathol Lab Med; 1990 Oct 01; 114(10):1017-20. PubMed ID: 2222141
    [Abstract] [Full Text] [Related]

  • 16. Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood.
    Giannitsis E, Baum H, Bertsch T, Juchum M, Müller-Bardorf M, Jørgensen B, Böhmer A, Rebmann M, Schäffler J, Schwab M, Zerback R.
    Clin Chem Lab Med; 2008 Oct 01; 46(5):630-8. PubMed ID: 18839464
    [Abstract] [Full Text] [Related]

  • 17. The clinical utility of CK-MB measurement in patients suspected of acute coronary syndrome.
    Kim J, Hashim IA.
    Clin Chim Acta; 2016 May 01; 456():89-92. PubMed ID: 26945601
    [Abstract] [Full Text] [Related]

  • 18. Analytical evaluation of methods for serum creatine kinase-MB. Electrophoresis, immunoinhibition and solid phase separation.
    Gadsden RH, Papadea CN, Cate JC.
    Ann Clin Lab Sci; 1994 May 01; 24(2):110-20. PubMed ID: 8203820
    [Abstract] [Full Text] [Related]

  • 19. Two radioimmunoassays compared with isoenzyme electrophoresis for the detection of serum creatine kinase-MB in acute myocardial infarction.
    Witherspoon LR, Shuler SE, Genre CF, Mackenzie FJ, Garcia MM.
    J Nucl Med; 1982 Feb 01; 23(2):136-42. PubMed ID: 7057255
    [Abstract] [Full Text] [Related]

  • 20. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
    Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW.
    Am J Cardiol; 2009 Nov 15; 104(10):1330-5. PubMed ID: 19892046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.